Total Funding
1
58
Total FundingSeed raised
Growth Score 1 in past quarter
-3 pts
Heat Score 58 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
164933
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
- Dennis Thiele: Chief Scientific Officer & Co-Founder
- Elyse Bourque: Vice President & Medicinal ChemistyPast Role: Centre for Drug Research and Development, Head Medicinal Chemistry
About the Company
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding: the underlying causes of neurodegenerative and other rare diseases.Their therapeutic approaches elevate the natural protein folding and stress protection mechanisms to prevent protein misfolding and the ensuing cell dysfunction and death. Chaperone’s
unique drug discovery platforms, broad knowledge in small molecule optimization and expertise in animal models of protein misfolding disease and clinical evaluation propel their therapeutic discovery programs forward.
Women Founded